Results 71 to 80 of about 16,312 (208)
, 2017 Hyperphosphatemia has been associated with adverse outcomes in patients with end stage kidney disease (ESKD). The purpose of this study was to determine risk factors for hyperphosphatemia in ESKD patients treated with peritoneal dialysis (PD).
Brendan McCormick +11 more
core +1 more source
Hypoparathyroidism and Avascular Necrosis of the Hip Joint: A Case Report
Clinical Case Reports, Volume 14, Issue 8, August 2026.ABSTRACT A 30‐year‐old man presented with left hip pain and was diagnosed with femoral head avascular necrosis associated with idiopathic hypoparathyroidism, hypocalcemia, and vitamin D deficiency. Treatment with calcium, calcitriol, analgesia, and physiotherapy improved symptoms. This case suggests hypoparathyroidism may play a role in the development
Munirah Altaissan +2 more
wiley +1 more source
, 2008 Vincenzo Savica1,2, Domenico Santoro1, Paolo Monardo2, Agostino Mallamace1, Guido Bellinghieri11Experimental and Clinic Department of Internal Medicine and Pharmacology, University of Messina, Italy; 2Nephrology and Dialysis Unit, Papardo Hospital ...
Guido Bellinghieri +4 more
core
Health Science Reports, Volume 9, Issue 8, August 2026.ABSTRACT Background and Aims Breast cancer continues to impose a considerable burden on women's health worldwide and represents one of the primary causes of cancer‐related mortality. Despite extensive research, regional data on its distribution and associated determinants remain essential.
Hourieh Ansari +3 more
wiley +1 more source
, 2017 Background: Calcium-based and non-calcium-based phosphate binders have similar efficacy in the treatment of hyperphosphatemia; however, calcium-based binders may be associated with hypercalcemia, vascular calcification, and adynamic bone disease ...
J Brian Copley, Rosamund J Wilson
core +1 more source
Novel Treatments from Inhibition of the Intestinal Sodium–Hydrogen Exchanger 3
International Journal of Nephrology and Renovascular Disease, 2021 Csaba P Kovesdy,1 Adebowale Adebiyi,2 David Rosenbaum,3 Jeffrey W Jacobs,3 L Darryl Quarles1 1Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN, USA; 2Department of Physiology, University of Tennessee Health Science ...
Kovesdy CP +4 more
doaj
, 2009 Veerle P Persy, Geert J Behets, Marc E De Broe, Patrick C D’HaeseLaboratory of Pathophysiology, University of Antwerp, BelgiumAbstract: Elevated serum phosphate levels as a consequence of chronic kidney disease (CKD) contribute to the increased
de Broe, Marc E. +7 more
core
A comprehensive study of phosphorus additives in foods and their effect on the American population [PDF]
, 2007 Includes bibliographical ...
Holliday, Mitchel
core
Efficacy of a Once-Daily Supplement in Managing Canine Chronic Kidney Disease
AnimalsBackground: Chronic kidney disease (CKD) in companion animals leads to progressive renal deterioration and metabolic complications such as hyperphosphatemia and metabolic acidosis, particularly in advanced stages.
Francesca Perondi +5 more
doaj +1 more source
The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease [PDF]
Терапевтический архив, 2016 Aim. To study whether the excessive production of serum fibroblast growth factor 23 (FGF-23) may be reduced with phosphate-binding agents to treat hyperphosphatemia in patients with Stage VD chronic kidney disease (CKD). Subjects and methods.
N A Mukhin +4 more
doaj